Yes that’s correct. They’ll get accelerated approval via breakthrough designation which moves things along more urgently than fast track. It’s an enormous benefit. AT did touch on it during the interview. I believe they will get that after the H2H results are released which will prove that patient outcomes are greatly improved because of earlier and more accurate detection from 64CuSAR-bis-PMSA compared to 68Ga-PMSA-11. As AT alluded to, it’s why both Lantheus and Telix have been in contact with him. They know what’s coming and they don’t like it one little bit.
CU6 Price at posting:
$1.52 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)